Moreover, our data prompted the involvement of the potential pathogenic role of MM-MSCs with alterations in osteogenesis and bone destruction, metabolism (e.g., glycolysis, fructose metabolic process, gluconeogenesis) and immunoregulatory response (e.g., positive regulation of TNF, inflammatory response, Th17 cell activation), together with hyperactivation of signaling cascades (e.g., IL2-STAT5 signaling, KRAS signaling). Here, KRAS is linked to Miyoshi myopathy.